UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve

European heart journal, 2016-05, Vol.37 (19), p.1504-1513

2016

Volltextzugriff (PDF)

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index

JNCI : Journal of the National Cancer Institute, 2020-12, Vol.112 (12), p.1266-1274

2020

Volltextzugriff (PDF)

Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma

Pancreas, 2008-08, Vol.37 (2), p.154-158

2008

Volltextzugriff (PDF)

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

Entropy (Basel, Switzerland), 2024-08, Vol.26 (8), p.687

2024

Volltextzugriff (PDF)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30

NPJ breast cancer, 2022-11, Vol.8 (1), p.123-7, Article 123

2022

Volltextzugriff (PDF)

A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials

Statistics in medicine, 2017-01, Vol.36 (2), p.280-290

2017

Volltextzugriff (PDF)

Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability

Journal of clinical oncology, 2022-02, Vol.40 (4), p.430-431

2022

Volltextzugriff (PDF)

Escalation with overdose control using time to toxicity for cancer phase I clinical trials

PloS one, 2014-03, Vol.9 (3), p.e93070

2014

Volltextzugriff (PDF)

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Statistical science, 2010-05, Vol.25 (2), p.217-226

2010

Volltextzugriff (PDF)

Comparison between continuous and discrete doses for model based designs in cancer dose finding

PloS one, 2019-01, Vol.14 (1), p.e0210139-e0210139

2019

Volltextzugriff (PDF)

Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control

Statistics in medicine, 2014-09, Vol.33 (22), p.3815-3829

2014

Volltextzugriff (PDF)

Translation of Innovative Designs Into Phase I Trials

Journal of clinical oncology, 2007-11, Vol.25 (31), p.4982-4986

2007

Volltextzugriff (PDF)

Phase I Trial of Preoperative Hypofractionated Intensity-Modulated Radiotherapy with Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer

International journal of radiation oncology, biology, physics, 2007-04, Vol.67 (5), p.1389-1393

2007

Volltextzugriff (PDF)

Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial

The American heart journal, 2021-07, Vol.237, p.90-103

2021

Volltextzugriff (PDF)

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

Journal of clinical oncology, 2021-12, Vol.39 (34), p.3800-3812

2021

Volltextzugriff (PDF)

On the properties of the toxicity index and its statistical efficiency

Statistics in medicine, 2021-03, Vol.40 (6), p.1535-1552

2021

Volltextzugriff (PDF)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

BMC medical research methodology, 2021-11, Vol.21 (1), p.1-244, Article 244

2021

Volltextzugriff (PDF)

Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma

Journal of clinical oncology, 2003-04, Vol.21 (7), p.1301-1306

2003

Volltextzugriff (PDF)

New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I

Clinical cancer research, 2005-08, Vol.11 (15), p.5342-5346

2005

Volltextzugriff (PDF)

A Bayesian adaptive design for cancer phase I trials using a flexible range of doses

Journal of biopharmaceutical statistics, 2018-05, Vol.28 (3), p.562-574

2018

Volltextzugriff (PDF)

Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer–Specific Quality of Life Questionnaire

Clinical therapeutics, 2021-07, Vol.43 (7), p.1245-1252

2021

Volltextzugriff (PDF)

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data

Quality of life research, 2023-03, Vol.32 (3), p.827-839

2023

Volltextzugriff (PDF)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04

Cancer, 2022-09, Vol.128 (17), p.3233-3242

2022

Volltextzugriff (PDF)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

PloS one, 2021-06, Vol.16 (6), p.e0252665-e0252665

2021

Volltextzugriff (PDF)

The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma

Clinical cancer research, 2001-05, Vol.7 (5), p.1181-1191

2001

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Englisch
(171)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index

Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30

A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials

Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability

Escalation with overdose control using time to toxicity for cancer phase I clinical trials

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Comparison between continuous and discrete doses for model based designs in cancer dose finding

Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control

Translation of Innovative Designs Into Phase I Trials

Phase I Trial of Preoperative Hypofractionated Intensity-Modulated Radiotherapy with Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer

Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

On the properties of the toxicity index and its statistical efficiency

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma

New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I

A Bayesian adaptive design for cancer phase I trials using a flexible range of doses

Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer–Specific Quality of Life Questionnaire

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma

Suchergebnisse filtern